Angelica Sette
Cambridge, ENG CB223AT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects.
Journal: Journal for immunotherapy of cancer
Published: March 24, 2025
Retraction Note: Development of novel anti-Kv 11.1 antibody-conjugated PEG-TiO2 nanoparticles for targeting pancreatic ductal adenocarcinoma cells.
Journal: Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology
Published: January 01, 2025
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Journal: Cancer discovery
Published: October 18, 2021
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.
Journal: British journal of cancer
Published: July 15, 2021
Development of novel anti-Kv 11.1 antibody-conjugated PEG-TiO2 nanoparticles for targeting pancreatic ductal adenocarcinoma cells.
Journal: Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology
Published: May 14, 2013
Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?
Journal: Biochimica et biophysica acta
Published: February 24, 2012
Theophylline is able to partially revert cachexia in tumour-bearing rats.
Journal: Nutrition & metabolism
Published: November 03, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026